Cytograft’s core platform technology is a natural, human, cell-derived implantable biomaterial that does not create an immune response. Cytograft is focused on the commercialization of aesthetic, cardiovascular, and diabetes products. Pipeline applications in wound care, orthobiologics, and bioprinting are being developed with collaborators and licensing partners.
“These non-immunogenic biomaterials are ideal for applications where long-term strength and durability is at a premium”
September 17, 2015- Dr. McAllister topresent at the Singular Research
conference in Los Angeles.